Pharmaceutical Medicine

, Volume 26, Issue 1, pp 45–47 | Cite as

Phase III ATENA Trial of Exemestane Discontinued

  • Mel Sweetlove
Trial Report


ATENA (Adjuvant post-Tamoxifen Exemestane versus Nothing Applied): a phase III randomized parallel-group multicenter trial, designed to compare 5 Years of adjuvant exemestane versus 5 years of observation in postmenopausal women with operable breast cancer who have received 5–7 years of adjuvant tamoxifen. The primary endpoint is disease-free survival. The effects of extended adjuvant therapy with exemestane on the lipid profile was a secondary endpoint. This trial was prematurely discontinued in November 2005 due to poor accrual following publication of the results of the MA.17 trial, which demonstrated a reduced risk of recurrence with extended adjuvant therapy using letrozole.


Tamoxifen Postmenopausal Woman Adjuvant Therapy Letrozole Exemestane 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Markopoulos C, et al. Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy. Breast Cancer Research 2009; 11 (3): R35PubMedCrossRefGoogle Scholar
  2. 2.
    Goss PE, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349 (19): 1793–802PubMedCrossRefGoogle Scholar
  3. 3.
    Clinical Breast cancer: exemestane [online]. Available from URL: [Accessed 2012 Jan 13]
  4. 4.
    Novartis International AG. Femara gains approval in Switzerland as only post-tamoxifen treatment for early breast cancer [media release]. 2004 Aug 12 [online]. Available from URL: [Accessed 2012 Jan 13]Google Scholar
  5. 5.
    Novartis Oncology. Femara® (letrozole tablets) gains U.S. FDA approval as only post-tamoxifen treatment for early breast cancer [media release]. 2004 Oct 29 [online]. Available from URL: [Accessed 2012 Jan 13]Google Scholar
  6. 6.
    Novartis. Femara® approved in Germany as the only hormonal therapy given after standard tamoxifen for post-menopausal womenwith early breast cancer [media release]. 2005 Mar 7 [online]. Available from URL: [Accessed 2012 Jan 13]Google Scholar
  7. 7.
    Novartis Pharmaceuticals Canada Inc. Health Canada approves first and only breast cancer treatment that improves disease-free survival beyond five years of diagnosis [media release]. 2005 Apr 11 [online]. Available from URL: [Accessed 2012 Jan 13]Google Scholar
  8. 8.
    di Salle E, et al. Exemestane (FCE 24304), a new steroidal aromatase inhibitor. J Steroid Biochem Mol Biol 1992; 43 (1–3): 137–43PubMedCrossRefGoogle Scholar
  9. 9.
    Haynes BP, et al. The pharmacology of letrozole. J Steroid Biochem Mol Biol 2003; 87 (1): 35–45PubMedCrossRefGoogle Scholar
  10. 10.
    Goss PE. Risks versus benefi ts in the clinical application of aromatase inhibitors. Endocr Relat Cancer 1999; 6 (2): 325–32PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2012

Authors and Affiliations

  • Mel Sweetlove
    • 1
  1. 1.AdisAucklandNew Zealand

Personalised recommendations